REX LEAR: Open Payments
NPI 1962445999 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,815 in 105 payments from 14 companies in 2025. Trend: 2023 $1,490 · 2024 $1,510 · 2025 $1,815
Food & beverage: $1,711Education: $104
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $283 |
| Otsuka America Pharmaceutical, Inc. | 23 | $265 |
| Janssen Pharmaceuticals, Inc | 10 | $240 |
| Vanda Pharmaceuticals Inc. | 9 | $225 |
| Teva Pharmaceuticals USA, Inc. | 6 | $189 |
| E.R. Squibb & Sons, L.L.C. | 7 | $187 |
| Alkermes, Inc. | 9 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $82 |
| ABBVIE INC. | 3 | $55 |
| Lundbeck LLC | 3 | $47 |
Products named: INGREZZA, REXULTI, COBENFY, FANAPT, INVEGA SUSTENNA, ARISTADA, SPRAVATO, CAPLYTA.
Industry payments across KS — which companies pay providers there.
